Myocardial Perfusion in Cardiac Amyloidosis
Liza Chacko(Imperial College London), Marianna Fontana(Amyloidosis Foundation), James Moon(University of Michigan), Daniel Knight(University College London), Peter Kellman(National Institutes of Health), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Mattia Riefolo(Azienda USL di Bologna), Ashutosh Wechelakar(MACOM (United States)), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Tim Lockie(Royal Free London NHS Foundation Trust), Charlotte Manisty(National Institutes of Health), Janet A. Gilbertson(The Royal Free Hospital), Rishi Patel(Texas Tech University), Kristopher Knott(University College London), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Hui Xue(National Institutes of Health), Carol Whelan(The Royal Free Hospital), Yousuf Razvi(The Royal Free Hospital), Aldostefano Porcari(Azienda Sanitaria Universitaria Integrata di Trieste), Tushar Kotecha(Royal Society), Ornella Leone(Policlinico S.Orsola-Malpighi), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Roby Rakhit(Royal Free London NHS Foundation Trust), Markella Ponticos(Centre for Inflammation Research), Niket Patel(Royal Free London NHS Foundation Trust), Adam Ioannou(The Royal Free Hospital), Paolo Massa(MACOM (United States)), Arantxa González(Instituto de Salud Carlos III)
Cited by 40
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k